The Matricellular Protein CCN5 (WISP2) inhibits Cellular Senescence in Cardiac Myocytes and Fibroblasts

The Matricellular Protein CCN5 (WISP2) inhibits Cellular Senescence in Cardiac Myocytes and Fibroblasts | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The Matricellular Protein CCN5 (WISP2) inhibits Cellular Senescence in Cardiac Myocytes and Fibroblasts Yongjoon Jo, Miyoung Lee, Sung Bin Kim, Tae Hwan Kwak, Dongtak Jeong, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7635827/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 20 Feb, 2026 Read the published version in Scientific Reports → Version 1 posted 12 You are reading this latest preprint version Abstract Cardiovascular diseases remain the leading cause of global mortality. Cellular senescence has recently been implicated in the pathogenesis of various cardiovascular diseases. Our group has previously shown that the matricellular protein CCN5 is a potent anti-fibrotic molecule capable of inhibiting and reversing cardiac fibrosis. In this study, we investigated whether CCN5 can modulate cellular senescence in the heart utilizing three readouts: western blotting for p53 and p21, staining for senescence-associated β-galactosidase, and microscopic analysis of γH2AX-positive foci. CCN5 effectively inhibited doxorubicin-induced cellular senescence in both cardiac myocytes and fibroblasts. In addition, CCN5 suppressed cellular senescence in cardiac myocytes induced by the senescence-associated secretory phenotype factors secreted from cardiac fibroblast, and vice versa . CCN5 also restored the apoptotic response of senescent cells. Finally, CCN5 attenuated myocardial infarction-induced cellular senescence in mice. Collectively, our findings provide novel insights into the potential role of CCN5 in the development of anti-senescence therapies. Health sciences/Cardiology Biological sciences/Cell biology Health sciences/Diseases CCN5 WISP2 Cellular senescence Cardiac myocytes Cardiac fibroblasts Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Introduction Cardiovascular diseases, including cardiomyopathy, arrhythmia, and heart failure, remain a leading cause of global mortality, with their prevalence increasing alongside an aging population 1 – 3 . Recent studies have shown that cellular senescence is closely linked to the pathogenesis and progression of diverse cardiovascular diseases by driving structural and functional alterations in the myocardium 4 – 6 . Stress-induced cellular senescence is a fundamental response to diverse insults such as DNA damage, mitochondrial dysfunction, and oncogenic activation. While it initially serves as a rapid protective mechanism, persistent senescence leads to detrimental consequences. Senescent cells are characterized by growth arrest, morphological changes, increased mitochondrial activity, and resistance to apoptotic stimuli. They also display a distinct phenotype known as the senescence-associated secretory phenotype (SASP), defined by the secretion of various cytokines, growth factors, and matrix metalloproteinases 7 – 9 . In the heart, senescent cells contribute to interstitial fibrosis, chronic inflammation, and extracellular matrix remodeling, thereby driving both diastolic and systolic dysfunction 4 – 6 . The limited regenerative capacity of the myocardium further exacerbates these age-related changes, increasing vulnerability to stressors such as metabolic overload, hypertension, and ischemic injury. More specifically, senescent cardiac myocytes develop hypertrophy, mitochondrial dysfunction, impaired contractility, and abnormal conduction, ultimately leading to progressive myocardial dysfunction. Senescent cardiac fibroblasts undergo proliferative arrest yet remain metabolically active, characterized by enhanced secretion of SASP-associated factors 10 , 11 . Two primary strategies have been proposed for targeting senescent cardiac cells. The first employs senolytic drugs to selectively eliminate senescent cells, while the second utilizes senomorphic drugs to suppress deleterious features such as SASP 12 , 13 . Although various nutritional and pharmacological interventions have been investigated 14 – 17 , their effectiveness in preventing or reversing senescence-associated pathologies remains limited, underscoring the urgent need for novel therapeutic strategies. Cell communication network (CCN) proteins (CCN1-6) are matricellular proteins that regulate diverse cellular processes, including fibrosis, angiogenesis, and wound healing. While most CCN proteins contain four distinct domains, IGFBP, vWC, TSP-1, and CT, CCN5 uniquely lacks the CT domain 18 , 19 . This structural distinction has led to the hypothesis that CCN5 may function as an endogenous inhibitor of other CCN members. Supporting this idea, our group has shown that CCN5 inhibits cardiac hypertrophy and fibrosis, at least in part, by counteracting CCN2 activity 20 – 22 . Previous studies further demonstrated that CCN1 and CCN2 promote fibroblast senescence 23 – 26 . Therefore, we hypothesized that CCN5 may regulate cellular senescence by antagonizing CCN1 or CCN2. In the present study, we investigated the role of CCN5 in cellular senescence using cultured rat cardiac myocytes and fibroblasts. Our results demonstrated that CCN5 suppressed cellular senescence induced by doxorubicin and by SASP factors in these cells. Moreover, CCN5 attenuated myocardial infarction (MI)-induced cellular senescence in the mouse heart. These findings suggest that CCN5 may serve as a potential therapeutic target for anti-senescence strategies in the heart. Results Doxorubicin (Dox) Induces Cellular Senescence in Cardiac Myocytes and Fibroblasts Doxorubicin (Dox) is known to induce cellular senescence in diverse cell types primarily by eliciting genotoxic stress 27 – 29 . To establish cellular senescence in cultured rat cardiac myocytes (H9c2) and cardiac fibroblasts, cells were treated with 100 nM Dox for 24 hours. Senescence was then assessed using three readouts. First, the expression of cell cycle regulators p53 and p21 was evaluated by western blotting. Second, senescent cells were quantified by microscopic detection of senescence-associated (SA) β-galactosidase activity. Third, accumulation of the DNA damage marker γH2AX was examined by immunostaining. All three assays consistently demonstrated that Dox effectively induced cellular senescence in both cardiac myocytes and fibroblasts (Supplementary Fig. 1). Accordingly, this protocol was employed in subsequent experiments to induce cellular senescence in vitro . CCN5 inhibits Dox-induced Cellular Senescence in Cardiac Myocytes and Fibroblasts We next examined whether CCN5 modulates Dox-induced cellular senescence in cardiac myocytes. After 24 hours of Dox treatment, the culture medium was replaced with fresh medium, and purified CCN5 protein (500 ng/mL) was added for an additional 24 hours (Fig. 1 A). CCN5 treatment reduced the expression levels of p53 and p21 (Fig. 1 B), decreased the number of SA-β-galactosidase-positive cells (Fig. 1 C), and lowered the number of γH2AX foci compared with untreated cells (Fig. 1 D). These results indicate that CCN5 suppresses cellular senescence in cardiac myocytes. We then performed similar experiments in cardiac fibroblasts (Fig. 2 A). As in cardiac myocytes, CCN5 treatment reduced the levels of senescent marker proteins (Fig. 2 B), decreased the number of SA-β-galactosidase-positive cells (Fig. 2 C), and diminished γH2AX foci (Fig. 2 D). Together, these findings demonstrated that CCN5 inhibits Dox-induced cellular senescence in both cardiac myocytes and fibroblasts. CCN5 Inhibits SASP-induced Cellular Senescence in Cardiac Myocytes and Cardiac Fibroblasts Senescent cells secret diverse factors, including cytokines, growth factors, and matrix metalloproteinases, collectively termed SASP factors. These factors exert paracrine effects that drive neighboring healthy cells into cellular senescence. Previous studies have shown that SASP secreted from cardiac myocyte can induce cellular senescence in adjacent fibroblasts 30 , 31 , and vice versa, thereby synergistically accelerating cellular senescence in the heart. We first tested whether CCN5 prevents cellular senescence in cardiac myocytes upon the treatment with SASP secreted from cardiac fibroblasts (Fig. 3 A). Cardiac fibroblasts were treated with Dox for 24 hours, followed by culture in fresh medium lacking Dox for an additional 24 hours. The resulting conditioned medium, enriched with SASP, was applied to cardiac myocytes in the presence or absence of purified CCN5 protein (500 ng/mL). Conditioned medium containing SASP induced cellular senescence in cardiac myocytes, as evidenced by elevated senescent markers (Fig. 3 B), an increased number of SA-β-galactosidase-positive cells (Fig. 3 C), and reduced γH2AX foci (Fig. 3 D). All these effects were significantly suppressed by CCN5 treatment. We next performed similar experiments to test whether CCN5 prevents cellular senescence in cardiac fibroblasts exposed to SASP secreted from cardiac myocytes (Fig. 4 A). In this setting, SASP secreted from cardiac myocytes induced cellular senescence in cardiac fibroblasts, as shown by all readouts, which was markedly attenuated by CCN5 (Fig. 4 B ~ D). Collectively, these findings demonstrated that CCN5 inhibits senescence not only induced by Dox but also triggered by SASP secreted from neighboring cardiac cell types. CCN5 Restores Apoptotic Responses in Senescent Cardiac Myocytes and Fibroblasts Senescent cells are resistant to apoptotic stimuli, and their persistence is particularly detrimental in chronic disease states. We therefore tested whether CCN5 could restore apoptotic responsiveness in cardiac myocytes and fibroblasts. Cells were treated with Dox for 24 hours, followed by purified CCN5 protein for an additional 24 hours, as described above. Apoptosis was then induced by treatment with staurosporine (STS, 100 nM) for 9 hours (Fig. 5 A, D) 32 . Western blotting revealed that cleaved PARP (c-PARP) and cleaved caspase 3 (c-Caspase 3) were significantly elevated in non-senescent cells (Cont), but not in Dox-treated senescent cells (Dox). This implies that the senescent cardiac myocytes and fibroblasts are indeed resistant to STS. CCN5 treatment restored sensitivity to STS in both cardiac myocytes and fibroblasts, as indicated by increased c-PARP and c-Caspase 3 levels (Dox + CCN5) (Fig. 5 B, E). Consistently, TUNEL assays showed a marked reduction in TUNEL-positive cells in senescent cells (Dox) compared with controls (Cont), which was significantly reversed by CCN5 treatment (Dox + CCN5) (Fig. 5 C, F). Together, these findings indicate that CCN5 normalizes the apoptotic response in senescent cardiac myocytes and fibroblasts. CCN5 Inhibits Senescence in an in vivo Mouse Heart Model We have previously shown that short-term expression of CCN5 via direct intramyocardial injection of modified mRNA encoding CCN5 (ModRNA-CCN5) significantly ameliorates structural and functional deterioration in mouse hearts subjected to myocardial infarction (MI) 33 , 34 . Using the same model, we investigated whether CCN5 also modulates cellular senescence in the infarcted heart. Coronary artery ligation to induce MI and intramyocardial injection of ModRNA-CCN5 were performed sequentially on the same day. Hearts were harvested on day 7 for molecular and histological analyses (Fig. 6 A). ModRNA-mediated expression of CCN5 was confirmed by western blotting (Supplementary Fig. 2). MI markedly increased of p53 and p21 expression (Fig. 6 B), the area and intensity of SA-β-galactosidase positive cells (Fig. 6 C), and the number of γH2AX-foci (Fig. 6 D) compared with sham-operated control hearts. CCN5 treatment significantly attenuated all of these cellular senescence-associated changes (Fig. 6 B ~ D). These findings indicate that CCN5 effectively inhibits cellular senescence in vivo in mouse heart following MI. Discussion This study demonstrates that CCN5 inhibits cellular senescence in cardiac myocytes and fibroblasts induced by Dox, a widely used reagent for senescence induction. We further showed that CCN5 prevents cellular senescence in these cells driven by SASP factors secreted from neighboring cells in a reciprocal manner. SASP-mediated secondary senescence drives a positive feedback loop that accelerates the expansion of senescent cells in vivo 5 . The anti-senescent effect of CCN5 was further validated in an in vivo model of MI-induced cardiac senescence. Collectively, these findings suggest that CCN5 represent a promising therapeutic target for modulating cellular senescence in the heart. Other CCN members have been reported to exert context-dependent roles in regulating cellular senescence. For example, CCN1 induces cellular senescence in multiple organs, including the skin, liver, and heart, and in diverse range of cell types, including fibroblasts, chondrocytes, and carcinoma cells 19 , 20 . CCN2 has been shown to promote cellular senescence in skin fibroblast, which helps to restrict fibrosis during tissue repair 21 , 22 . Furthermore, CCN1 and CCN3 have been directly implicated in the pathology of osteoarthritis by inducing chondrocyte senescence 35 – 37 . This study was motivated by our previous findings that CCN5 antagonizes CCN2 activity in both the heart 20 , 21 and eye 38 – 40 . CCN2 expression is elevated in failing hearts under various pathological insults and is closely associated with cardiac fibrosis. We previously demonstrated that CCN5 inhibits cardiac fibrosis at least in part by downregulating CCN2. Similarly, CCN2 levels are elevated in the mouse retina under multiple pathogenic conditions and are linked to neovascularization and degeneration of retinal pigmented epithelium. In this contexts as well, CCN5 suppressed retinal pathologies while concomitantly reducing CCN2 expression. Based on these findings, we hypothesized that CCN5 may inhibit cellular senescence in the heart by antagonizing CCN2 and possibly other CCN family members. Although our data clearly demonstrate that CCN5 inhibits cellular senescence in the heart, the underlying molecular mechanism remains unclear. For example, CCN2 expression levels were unaltered following treatment with Dox 41 or SASP (data not shown). suggesting that suppression of the CCN2 is unlikely to account for the anti-senescence activity of CCN5. We previously showed that CCN5 reverses pre-formed cardiac fibrosis by actively inducing the reverse trans-differentiation of myofibroblasts 19 . By analogy, CCN5 may similarly trigger a reverse process of cellular senescence. Given that CCN5 modulates cellular senescence induced by Dox and SASP, it may serve as a senomorphic strategy by preventing the onset of senescence. Moreover, through its ability to restore apoptotic sensitivity in senescent cells, CCN5 may also function as a senolytic strategy, promoting the removal of existing senescent cells. Overall, this study elucidates an anti-senescent function CCN5 in the heart. Together with its previously identified anti-fibrotic activity, these findings position CCN5 as a promising therapeutic modality for a broad spectrum of heart diseases. Methods Cells and cell culture Rat ventricular cardiac fibroblasts (Cell Applications) were cultured in FGM medium (Cell Applications). H9c2 cells were cultured in High-Glucose DMEM (HyClone, Cytiva) at 37°C in a 5% CO 2 incubator. HEK 293-F cells (Gibco, #R79007) were suspension-cultured in Freestyle 293 medium (Gibco, #12338018) at 37°C in an 8% CO 2 incubator with continuous shaking. Purification of Recombinant Proteins cDNAs encoding the full-length human CCN5 protein were subcloned into a pcDNA3.1-myc-his plasmid and subsequently transfected into HEK 293-F cells. One day prior to transfection, 1 x 10 6 cells were seeded into Freestyle 293 medium. On the day of transfection, plasmid DNA was diluted in Opti-MEM medium (Gibco, #51985034). FectoPRO transfection reagent (Polyplus, #116–001) was then added to the diluted plasmid DNA at a 1:1 ratio, and the mixture was incubated for 10 minutes at room temperature. The mixture was added to the cultured HEK 293-F cells. Three days’ post-transfection, the culture medium was collected and centrifuged at 2,000 × g for 10minutes. Proteins from the culture medium were purified using Capturem His-Tagged Purification Maxiprep Columns (Takara, #635715). The purified proteins were stored in a buffer containing 20 mM NaHPO 4 , 150 mM NaCl, and 250 mM imidazole at -70°C 42 . Induction of Senescence, CCN5 Treatment, and SASP-Containing Media Preparation Senescence was induced by administering doxorubicin (100 nM) to cells in growth media for 24 hours. Purified CCN5 protein (500ng/ml) was added to cells for 24hours in media containing 0.1% FBS. Staurosporine (100nM) was applied to cells after CCN5 treatment for 9hours. To test SASP, following 24hours of doxorubicin treatment and a single wash with PBS, the medium was replaced with growth medium containing 0.1% FBS to remove doxorubicin. Cells were then incubated for 24 hours to generate SASP-containing conditioned media (CM). CM were treated with CCN5 protein for 24hour. Western Blotting Cell lysates were solubilized in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, pH 8.0) supplemented with Protease Inhibitor Cocktail Set III (Merck Millipore, #535140). Cell lysates were quantified using a Pierce BCA Protein Assay Kit (Thermo Scientific, #23227), separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to polyvinylidene difluoride (PVDF) membranes (Merck Millipore, #IPVH00010). Blots were blocked with a 3% BSA solution and incubated with primary antibodies against p53(Abcam), p21(Abcam), p16 (Abcam, #ab32072), GAPDH (CST), beta-actin (Santa Cruz), PARP(CST), caspase3(CST) and cleaved-caspase3(CST) for 12–16 hours at 4°C. After washing with Tris-buffered saline containing 0.1% Tween 20 (TBS-T), blots were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Thermo Scientific, #31460 for rabbit, #31430 for mouse), and washed again. Signals were developed using a EZ-Western Lumi Pico Kit (Dogenbio, Seoul, Korea) and Western Femto ECL Kit (FEMTO-100) and were detected by Amersham™ ImageQuant™ 800 (Cytiva). Senescence-associated βgalactosidase (SA-βgal) assay SA-βgal assay was assessed according to the manufacturer’s protocol (CST #9860). For in vitro SA-βgal assay, fibroblasts and myocytes were seeded on 6-well plates. Fluorescence microscopy and DIC images were captured from random fields in each well using an EVOS M7000. SA-βgal positive cells are normalized against Hoechst-positive nucleus. For in vivo SA-βgal assay, frozen heart tissues were outlined with ImmEdge® Hydrophobic Barrier PAP Pen (H-4000) and soaked in SA-βgal staining solution. Fluorescence microscopy and DIC images were captured using Olympus research slide scanner. All assays were performed in at least triplicate, with at least 300-500cells counted per sample from randomly selected fields. SA-βgal signals were analyzed using ImageJ software. The same settings (threshold, color threshold, brightness, analyze particles) were applied for each experimental set. Color Thresholding was applied to selectively retain the blue-colored SA-βgal stained regions. Thresholding process was employed to eliminate background noise, enabling the accurate determination and analysis of both nuclei and the SA-βgal stained areas. Immunocytochemistry Cells were seeded onto 16 mm coverslips. After CCN5 treatment, cells were fixed with 4% PFA, permeabilized with 0.2% Triton X-100, and blocked with a 5% BSA solution. Subsequently, cells were incubated with a primary antibody against γH2AX (JBW301, Merck), followed by incubation with Alexa Fluor 488 (Invitrogen, A11008) conjugated secondary antibodies. Hoechst 33342 dye was used for nuclear staining. Fluorescence microscopy images were captured using an Olympus fluorescent microscope. All assays were performed in at least triplicate, with at least 100 cells counted per sample from randomly selected fields. Immunofluorescence signals were analyzed using ImageJ software, applying the same settings (threshold, Gaussian distribution, analyze particles) for each experiment set. A Gaussian distribution-based image subtraction was applied to remove noise and extract foci. A thresholding process was also employed to eliminate background noise, enabling the accurate quantification and analysis of both nuclei and the γH2AX foci. TUNEL Assay TUNEL assay was performed according to the manufacturer’s instructions (DeadEnd Fluorometric TUNEL System (Promega, San Luis Obispo, CA, USA). The slides with seeded cells were treated with a TUNEL reaction mixture containing terminal deoxynucleotidyl transferase (TdT) and fluorescein UTP. The reaction was carried out in a humidified chamber at 37 ◦C for 1 hour. After the reaction, the slides were stained with Hoechst 33342 and examined under a fluorescent microscope (Olympus). Apoptotic signals and nuclear signals were counted using ImageJ software with a fixed threshold for each experiment, and the percentage of TUNEL-positive cells was calculated. Animal Experiments and Myocardial Infarction Model All animal experimental procedures were approved by the Institutional Animal Care and Use Committees of Gwangju Institute of Science and Technology (GIST). All procedures were conducted in accordance with relevant guidelines and regulations for laboratory animals. This study is reported in accordance with ARRIVE guidelines. C57BL/6 mice (10–12-week-old males, 25–28 g body weight) were obtained from DBL Inc. (Eumseong, Korea). All efforts were made to minimize animal suffering. All mice were housed in an equipped animal facility with temperature of 18–23°C and humidity at 40–60%, under 12hous light/dark cycle, and had free access to food and water. To induce myocardial infarction model, mice were anesthetized by a mixture of 95 mg/kg ketamine (Yuhan, Korea) and 5 mg/kg xylazine (Bayer, Germany). The left side of the chest was shaved, and an intubation tube was inserted into the trachea. An incision was made in the fourth intercostal space, and the muscles were separated with scissors. The pericardium was gently removed. Myocardial infarction (MI) was induced by ligation of the left anterior descending (LAD) artery using a 7 − 0 black silk suture. The chest was sutured with 4 − 0 black silk. The same surgical procedure, without LAD ligation, was performed for the sham operation. Seven days post-surgery, isoflurane was used for anesthetization via inhalation before euthanasia. Mice were euthanized by cervical dislocation humanely performed by trained researchers in accordance with approved protocols. Harvested hearts were used for western blotting, senescence-associated β-galactosidase (SA-β-gal) assay, and immunohistochemistry. Production of Modified mRNA-CCN5 and Injection Polyadenylated and capped (CleanCap™ technology) modified RNAs (ModRNAs) were synthesized by TriLink Biotechnologies (San Diego, CA, USA) with full substitution of uridine with pseudo-uridine. The 5′ and 3′ untranslated regions (UTRs) were designed by the Zangi lab (New York, NY, USA). ModRNAs and Lipofectamine RNAiMAX transfection reagent (Invitrogen, Waltham, MA, USA, #13778150) were separately diluted in Opti-MEM, mixed, and incubated for 15 minutes at room temperature. A total of 50 µg of the ModRNA mixture was directly injected into the endocardium adjacent to the infarcted area. Histology and Immunohistochemistry Harvested tissue samples were fixed in 4% paraformaldehyde for 72 hours at 4°C and incubated in 30% sucrose for 72 hours at 4°C as a cryoprotectant. The tissues were embedded in OCT compound (3801480, Leica, Germany). Frozen tissue blocks were sectioned at 8 µm thickness using a cryostat microtome (HM525NX, Thermo Scientific, USA). Sections were mounted on adhesive slides (J1800AMNZ, Epredia). For γH2AX, immunohistochemistry was performed, which included antigen retrieval by boiling in a pH 6 citrate buffer. Primary antibodies (JBW301, Merck, 1:250) were diluted in a 3% bovine serum albumin blocking solution and applied for incubation. Secondary Alexa Fluor 594 (Invitrogen, A11032) conjugated antibodies were then applied and visualized. Images were acquired using Olympus confocal microscopy (Olympus, Japan). Immunofluorescence signals were analyzed using ImageJ software applying the same settings (threshold, Gaussian distribution, analyze particles) for each experiment set. A Gaussian distribution-based image subtraction was applied to remove noise and extract foci. A thresholding process was employed to eliminate background noise, enabling the accurate quantification and analysis of both nuclei and the γH2AX foci. Statistical Analysis N numbers represent independent biological observations. All experiments were repeated independently at least three times. One-Way Analysis of Variance (ANOVA) was employed for statistical analyses to determine the significance of the data using GraphPad Prism 7 software (GraphPad Software, San Diego, CA). An asterisk (*, p ≤ 0.05) or a double asterisk (**, p ≤ 0.01) indicates statistical significance. Data are presented as the mean ± standard deviation. Declarations Competing interests No potential conflicts of interest exist for other authors. Funding This study was supported by funding from the Korea–US Collaborative Research Fund (RS-2024-00466906) and the National Research Council of Science & Technology(NST) grant by the Korea government (MSIT) (No. GTL24021-000). Author Contribution Conceptualization, S.P.J. and W.J.P.; methodology, J.Y.J. and M.Y.L.; validation, S.B.K., J.Y.J. and M.Y.L.; formal analysis, J.Y.J.; investigation, J.Y.J.; data curation, S.B.K. and S.P.J.; writing—original draft preparation, J.Y.J.; writing—review and editing, J.Y.J., S.P.J. and W.J.P.; supervision, S.P.J. and W.J.P.; Resources, T.H.K. and D.T.J.; project administration, W.J.P.; funding acquisition, W.J.P. Acknowledgement We thank Dr. YS. Oh (Central Research Facility of Gwangju Institute of Science and Technology) for technical assistance of the confocal microscopy. Figures 1 A, 2 A, 3 A, 4 A, 5A and 5D were created with BioRender.com. (https://www.biorender.com, https://BioRender.com/w1x0kdx). During the preparation of this manuscript, the authors used ChatGPT (version 5.0) to assist with proofreading and improving the readability of the manuscript. All content was reviewed and edited by the authors, who take full responsibility for the final version of the publication. Data Availability All relevant data are within this paper and its Supporting Information files. The datasets used or analyzed during this study are available from the corresponding authors upon reasonable request. References Martin, S. S. et al. 2025 Heart Disease and Stroke Statistics: A report of US and global data from the American Heart Association. Circulation (2025) doi:10.1161/ cir.0000000000001303. Beghini, A. et al. 2024 update in heart failure. ESC Heart Failure (2024) doi:10.1002/ ehf2.14857. World Health Organization: WHO Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2025). Luan, Y. et al. Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets. Cell Death Discovery 10 , (2024). Grootaert, M. O. J. Cell senescence in cardiometabolic diseases. Npj Aging 10 , (2024). Evangelou, K. et al. Cellular senescence and cardiovascular diseases: moving to the “heart” of the problem. Physiological Reviews 103 , 609–647 (2022). González‐Gualda, E., Baker, A. G., Fruk, L. & Muñoz‐Espín, D. A guide to assessing cellular senescencein vitroandin vivo. FEBS Journal 288 , 56–80 (2020). Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179 , 813–827 (2019). Kumari, R. & Jat, P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. Frontiers in Cell and Developmental Biology 9 , (2021). Shimizu, I. & Minamino, T. Cellular senescence in cardiac diseases. Journal of Cardiology 74 , 313–319 (2019). Zhao, S., Zhang, Y., Zhao, Y. & Lu, X. Cellular senescence as a key player in Chronic heart failure pathogenesis: unraveling mechanisms and therapeutic opportunities. Progress in Biophysics and Molecular Biology (2025) doi:10.1016/j.pbiomolbio.2025.02.002. Stojanović, S. D., Thum, T. & Bauersachs, J. Anti-senescence therapies: a new concept to address cardiovascular disease. Cardiovascular Research (2025) doi:10.1093/cvr/cvaf030. Suda, M., Katsuumi, G., Tchkonia, T., Kirkland, J. L. & Minamino, T. Potential clinical implications of senotherapies for cardiovascular disease. Circulation Journal 88 , 277–284 (2023). Xia, W. et al. Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity. FEBS Journal (2024) doi:10.1111/febs.17164. Scalise, M. et al. Senolytics rejuvenate aging cardiomyopathy in human cardiac organoids. Mechanisms of Ageing and Development 112007 (2024) doi:10.1016/j.mad.2024.112007. Salerno, N. et al. Pharmacological clearance of senescent cells improves cardiac remodeling and function after myocardial infarction in female aged mice. Mechanisms of Ageing and Development 208 , 111740 (2022). Yang, B. et al. Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway. International Journal of Biological Sciences 20, 4314–4340 (2024). Monsen, V. T. & Attramadal, H. Structural insights into regulation of CCN protein activities and functions. Journal of Cell Communication and Signaling 17 , 371–390 (2023). Chen, C.-C. & Lau, L. F. Functions and mechanisms of action of CCN matricellular proteins. The International Journal of Biochemistry & Cell Biology 41 , 771–783 (2008). Jeong, D. et al. Matricellular protein CCN5 reverses established cardiac fibrosis. Journal of the American College of Cardiology 67 , 1556–1568 (2016). Yoon, P. O. et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. Journal of Molecular and Cellular Cardiology 49 , 294–303 (2010). Zhang, L., Li, Y., Liang, C. & Yang, W. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. International Journal of Molecular Medicine 33 , 478–486 (2013). Feng, T. et al. CCN1-Induced cellular senescence promotes heart regeneration. Circulation 139 , 2495–2498 (2019). Jun, J.-I. & Lau, L. F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nature Cell Biology 12 , 676–685 (2010). Jun, J.-I. & Lau, L. F. CCN2 induces cellular senescence in fibroblasts. Journal of Cell Communication and Signaling 11 , 15–23 (2016). Tejedor-Santamaria, L. et al. CCN2 activates cellular senescence leading to kidney fibrosis in folic Acid-Induced experimental nephropathy. International Journal of Molecular Sciences 26 , 4401 (2025). Von Hoff, D. D. Risk factors for doxorubicin-lnduced congestive heart failure. Annals of Internal Medicine 91 , 710 (1979). Maejima, Y., Adachi, S., Ito, H., Hirao, K. & Isobe, M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. Aging Cell 7 , 125–136 (2007). Spallarossa, P. et al. Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. AJP Heart and Circulatory Physiology 297 , H2169–H2181 (2009). Tang, X., Li, P.-H. & Chen, H.-Z. Cardiomyocyte senescence and cellular communications within myocardial microenvironments. Frontiers in Endocrinology 11 , (2020). Lewis‐McDougall, F. C. et al. Aged‐senescent cells contribute to impaired heart regeneration. Aging Cell 18 , (2019). Kato, K. et al. Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. American Journal of Respiratory Cell and Molecular Biology 62 , 633–644 (2020). Magadum, A. et al. Specific Modified mRNA translation System. Circulation 142 , 2485–2488 (2020). Song, M. H. et al. Modified mRNA-Mediated CCN5 Gene Transfer Ameliorates Cardiac Dysfunction and Fibrosis without Adverse Structural Remodeling. International Journal of Molecular Sciences 25 , 6262 (2024). Feng, M. et al. Inhibition of cellular communication network factor 1 (CCN1)-driven senescence slows down cartilage inflammaging and osteoarthritis. Bone 139 , 115522 (2020). Kuwahara, M. et al. CCN3 (NOV) drives degradative changes in aging articular cartilage. International Journal of Molecular Sciences 21 , 7556 (2020). Fujita, M., Sasada, M., Iyoda, T. & Fukai, F. Involvement of matricellular proteins in cellular senescence: Potential therapeutic targets for Age-Related Diseases. International Journal of Molecular Sciences 25 , 6591 (2024). Im, S., Song, M. H., Elangovan, M., Woo, K. M. & Park, W. J. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium. Scientific Reports 14 , (2024). Yoon, A. et al. The matricellular protein CCN5 inhibits fibrotic deformation of retinal pigment epithelium. PLoS One 13 , e0208897, doi:10.1371/journal.pone.0208897 (2018). Im, S. et al. Suppression of choroidal neovascularization and epithelial-mesenchymal transition in retinal pigmented epithelium by adeno-associated virus-mediated overexpression of CCN5 in mice. PLoS One 17 , e0269937, doi:10.1371/journal.pone.0269937 (2022). Patricelli, C., Lehmann, P., Oxford, J. T. & Pu, X. Doxorubicin-induced modulation of TGF-β signaling cascade in mouse fibroblasts: insights into cardiotoxicity mechanisms. Scientific Reports 13 , (2023). Song, M. H. et al. The TSP-1 domain of the matricellular protein CCN5 is essential for its nuclear localization and anti-fibrotic function. PLoS ONE 17 , e0267629 (2022). Additional Declarations No competing interests reported. Supplementary Files JoetalScireportsupplementarydataRev.pdf Cite Share Download PDF Status: Published Journal Publication published 20 Feb, 2026 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 13 Oct, 2025 Reviews received at journal 12 Oct, 2025 Reviews received at journal 30 Sep, 2025 Reviewers agreed at journal 29 Sep, 2025 Reviews received at journal 26 Sep, 2025 Reviewers agreed at journal 26 Sep, 2025 Reviewers agreed at journal 24 Sep, 2025 Reviewers invited by journal 24 Sep, 2025 Editor assigned by journal 24 Sep, 2025 Editor invited by journal 24 Sep, 2025 Submission checks completed at journal 22 Sep, 2025 First submitted to journal 22 Sep, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7635827","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":525043808,"identity":"3c611e9f-753e-47a2-9c62-2216b06d23e6","order_by":0,"name":"Yongjoon Jo","email":"","orcid":"","institution":"Gwangju Institute of Science and Technology","correspondingAuthor":false,"prefix":"","firstName":"Yongjoon","middleName":"","lastName":"Jo","suffix":""},{"id":525043809,"identity":"ebfdc972-4bee-4e19-b10c-3e45661d4d03","order_by":1,"name":"Miyoung Lee","email":"","orcid":"","institution":"Gwangju Institute of Science and Technology","correspondingAuthor":false,"prefix":"","firstName":"Miyoung","middleName":"","lastName":"Lee","suffix":""},{"id":525043810,"identity":"dcbc59a4-70c5-4cea-975e-8cf2abf7cbff","order_by":2,"name":"Sung Bin Kim","email":"","orcid":"","institution":"Gwangju Institute of Science and Technology","correspondingAuthor":false,"prefix":"","firstName":"Sung","middleName":"Bin","lastName":"Kim","suffix":""},{"id":525043811,"identity":"c4bb8d2c-93cc-432a-9470-cfb8dc631d9f","order_by":3,"name":"Tae Hwan Kwak","email":"","orcid":"","institution":"BethphaGen","correspondingAuthor":false,"prefix":"","firstName":"Tae","middleName":"Hwan","lastName":"Kwak","suffix":""},{"id":525043812,"identity":"6ae963d6-a21b-40b6-abd6-dabbe0a75221","order_by":4,"name":"Dongtak Jeong","email":"","orcid":"","institution":"Hanyang University-ERICA","correspondingAuthor":false,"prefix":"","firstName":"Dongtak","middleName":"","lastName":"Jeong","suffix":""},{"id":525043813,"identity":"96beba40-825a-4678-a505-b1b82415ca2f","order_by":5,"name":"Seung Pil Jang","email":"","orcid":"","institution":"Korea Research Institute of Bioscience and Biotechnology","correspondingAuthor":false,"prefix":"","firstName":"Seung","middleName":"Pil","lastName":"Jang","suffix":""},{"id":525043814,"identity":"90c52a5d-ed1a-4c26-ac36-08a34c033322","order_by":6,"name":"Woo Jin Park","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA00lEQVRIiWNgGAWjYJACgwQQycN84ABDAZBxgHgtbAkHGAyI1AIBPDxA9cRoMTjefKDg4Y478uY9Zz4e+GFgk9h3gPnhoxv4tJw5lmCQeOaZ4ZyzvRsO9hikJc48wGZsnINHi9mNHAODxLbDjDP4eTccZjA4nLjhAA+bNDFa7Gfw8zwgTUviDN4eBuK02IP90vYseQbPMQOQX4xnHibgF8n25mOGP9vu2M7gSX784UeFjWzf8eaHj/FpAQI2A9S4YMavHKzkASkxPgpGwSgYBSMQAACN91c97wYw6wAAAABJRU5ErkJggg==","orcid":"","institution":"Gwangju Institute of Science and Technology","correspondingAuthor":true,"prefix":"","firstName":"Woo","middleName":"Jin","lastName":"Park","suffix":""}],"badges":[],"createdAt":"2025-09-17 05:08:27","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7635827/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7635827/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-026-40206-1","type":"published","date":"2026-02-20T15:58:41+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":92930553,"identity":"f5048cef-b006-4d9e-a972-c20ba10cbc9e","added_by":"auto","created_at":"2025-10-07 08:58:28","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1511800,"visible":true,"origin":"","legend":"","description":"","filename":"JoetalScireportRev.docx","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/0f00a11a028aeea378541eef.docx"},{"id":92930554,"identity":"071d07c9-f156-435a-983a-a89bcd0ba670","added_by":"auto","created_at":"2025-10-07 08:58:28","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":8572,"visible":true,"origin":"","legend":"","description":"","filename":"933037c2f8d84bdb997460c9cb5efb99.json","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/d44020f628339408ac371abe.json"},{"id":92929419,"identity":"0e4faa80-5932-463a-9a4a-b9c6c518d975","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1095397,"visible":true,"origin":"","legend":"","description":"","filename":"JoetalScireportsupplementarydataRev.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/13b954f58335e5434d6c188d.pdf"},{"id":92929411,"identity":"f675e505-5d12-4fea-afd3-47732d871b98","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":103778,"visible":true,"origin":"","legend":"","description":"","filename":"933037c2f8d84bdb997460c9cb5efb991enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/c11e44cc8a3b8af289d67cef.xml"},{"id":92929409,"identity":"6067a88d-58b5-49e7-9f72-727cbe545827","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":51452,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/0b879a9a96f0b9513c2a0429.png"},{"id":92929620,"identity":"39a9cbd7-140d-4c35-bf1f-1048111d8285","added_by":"auto","created_at":"2025-10-07 08:50:28","extension":"png","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":59916,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/685d5865a508aafbf3f4542f.png"},{"id":92929414,"identity":"4d4ffaa6-4a5f-49a4-bfe8-a2425871ba3c","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"png","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":61891,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/b90dc2cc50d44926242697ae.png"},{"id":92929619,"identity":"b7386e15-185e-43dd-89f2-1575cc863f16","added_by":"auto","created_at":"2025-10-07 08:50:28","extension":"png","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":56862,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage4.png","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/67d91d62df2a97df25a03c9c.png"},{"id":92929420,"identity":"7e274ae4-3f3e-4e1d-9d46-6a204aae5f35","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"png","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":74046,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage5.png","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/8e2b7947ebed5e2f8c7fabd4.png"},{"id":92929415,"identity":"004ddc54-836a-42af-a495-e64fdccc7bb8","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"png","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":128478,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage6.png","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/1b2cd608413284e469afc635.png"},{"id":92929421,"identity":"20e0e5a2-c8b6-49b7-acdc-b70a2534fec2","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"xml","order_by":16,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":100266,"visible":true,"origin":"","legend":"","description":"","filename":"933037c2f8d84bdb997460c9cb5efb991structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/a98967dfb45fba0be087fe2c.xml"},{"id":92929622,"identity":"d802c9ec-6662-4c70-9298-aca2162e2609","added_by":"auto","created_at":"2025-10-07 08:50:28","extension":"html","order_by":17,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":114156,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/100d49fc33fdd6715ab83312.html"},{"id":92930552,"identity":"1265a0d4-3e1c-4ed4-8bf3-fe6fd588d706","added_by":"auto","created_at":"2025-10-07 08:58:28","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":211110,"visible":true,"origin":"","legend":"\u003cp\u003eCCN5 inhibits Dox-induced Cellular Senescence in Cardiac Myocytes. (A) An experimental scheme is shown (created using Biorender). (B) H9c2 cardiac myocytes were treated with Dox, followed by CCN5 treatment. Cell lysates were immunoblotted for senescence marker proteins p53 and p21. Protein levels were quantified and normalized to GAPDH (n=4). Panel B is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. (C) H9c2 cells were stained for SA-β-gal activity. Positive cells were counted in random fields and plotted as a percentages of total cell number (n=3) (D) H9c2 cells were immunostained with antibodies against γH2AX (green) and counter-stained with Hoechst (blue). γH2AX foci were counted in random fields and plotted as a percentage of total nuclei (n=3). Scale bar: 50 μm. Data are shown as the mean ± SD. (one-way ANOVA; *p \u0026lt; 0.05, **p \u0026lt; 0.01).\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/50913c3e74f6dd7bd192b04e.jpeg"},{"id":92929404,"identity":"11f9dcb5-f627-40a2-9683-a5f782701efe","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":228722,"visible":true,"origin":"","legend":"\u003cp\u003eCCN5 inhibits Dox-induced Cellular Senescence in Cardiac Fibroblasts. (A) An experimental scheme is shown (created using Biorender). (B) RCFs were treated with Dox, followed by CCN5 treatment. Cell lysates were immunoblotted for senescence marker proteins p53 and p21. Protein levels were quantified and normalized to GAPDH (n=4). Panel B is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. (C) RCFs were stained for SA-β-gal activity. Positive cells were counted in random fields and plotted as a percentages of total cell number (n=3) (D) RCFs were immunostained with antibodies against γH2AX (green) and counter-stained with Hoechst (blue). γH2AX foci were counted in random fields and plotted as a percentage of total nuclei (n=3). Scale bar: 50 μm. Data are shown as the mean ± SD. (one-way ANOVA; *p \u0026lt; 0.05, **p \u0026lt; 0.01).\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/15ed59d015752654aee1a64d.jpeg"},{"id":92929614,"identity":"ce3f8493-ee79-4042-915e-bbe882447efc","added_by":"auto","created_at":"2025-10-07 08:50:28","extension":"jpeg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":237100,"visible":true,"origin":"","legend":"\u003cp\u003eCCN5 Inhibits Cellular Senescence of Cardiac Myocytes Induced by SASP from Fibroblasts. (A) An experimental scheme is shown (created using Biorender). (B) H9c2 cardiac myocytes were treated with Dox-media or CCN5. Cell lysates were immunoblotted for senescence marker proteins p53 and p21. Protein levels were quantified and normalized to GAPDH (n=4). Panel B is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. (C) H9c2 cells were stained for SA-β-gal activity. Positive cells were counted in random fields and plotted as a percentages of total cell number (n=3~4) (D) H9c2 cells were immunostained with antibodies against γH2AX (green) and counter-stained with Hoechst (blue). γH2AX foci were counted in random fields and plotted as a percentage of total nuclei (n=3). Scale bar: 50 μm. Data are shown as the mean ± SD. (one-way ANOVA; *p \u0026lt; 0.05, **p \u0026lt; 0.01). Dox-media = Doxorubicin treated and SASP-containing conditioned medium\u003c/p\u003e","description":"","filename":"floatimage3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/67653bf7e9c7e6c9c4baad19.jpeg"},{"id":92929613,"identity":"a4efbed8-275d-4d0e-9533-c34427f972e6","added_by":"auto","created_at":"2025-10-07 08:50:28","extension":"jpeg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":234288,"visible":true,"origin":"","legend":"\u003cp\u003eCCN5 Inhibits Cellular Senescence of Cardiac Fibroblasts Induced by SASP from Cardiac Myocytes. (A) An experimental scheme is shown (created using Biorender). (B) RCFs were treated with Dox-media or CCN5. Cell lysates were immunoblotted for senescence marker proteins p53 and p21. Protein levels were quantified and normalized to GAPDH (n=4). Panel B is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. (C) RCFs were stained for SA-β-gal activity. Positive cells were counted in random fields and plotted as a percentages of total cell number (n=3) (D) RCFs were immunostained with antibodies against γH2AX (green) and counter-stained with Hoechst (blue). γH2AX foci were counted in random fields and plotted as a percentage of total nuclei (n=3). Scale bar: 50 μm. Data are shown as the mean ± SD. (one-way ANOVA; *p \u0026lt; 0.05, **p \u0026lt; 0.01). Dox-media = Doxorubicin treated and SASP-containing conditioned medium\u003c/p\u003e","description":"","filename":"floatimage4.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/186b75e209f734109107f03d.jpeg"},{"id":92929412,"identity":"6221120a-b20a-4636-812b-ac424becc1ab","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"jpeg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":290211,"visible":true,"origin":"","legend":"\u003cp\u003eCCN5 Restores Apoptotic Responses in Senescent Cardiac Myocytes and Fibroblasts. (A) An experimental schema is shown for B and C (created using Biorender). (B) H9c2 cardiac myocytes were treated with Dox, followed by CCN5 treatment and then STS. Cell lysates were immunoblotted for apoptosis marker proteins c-PARP and c-caspase3. Protein levels were quantified and normalized to GAPDH (n=4~7). Panel B is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. \u0026nbsp;(C) H9c2 were stained for TUNEL assay; TUNEL positive cells were counted in random fields and plotted as percentages of total cell number (N=3). (D) An experimental schema is shown for E and F (created using Biorender). (E) RCFs were treated with Dox, followed by CCN5 treatment and then STS. Cell lysates were immunoblotted for apoptosis marker proteins c-PARP and c-caspase3. Protein levels were quantified and normalized to GAPDH (n=4~7). Panel E is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. \u0026nbsp;(F) RCFs were stained for TUNEL assay; TUNEL positive cells were counted in random fields and plotted as percentages of total cell number (N=3). Scale bar: 50 μm. Data are shown as the mean ± SD. (one-way ANOVA; *p \u0026lt; 0.05, **p \u0026lt; 0.01).\u003c/p\u003e","description":"","filename":"floatimage5.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/02732d4b13fb45dd18025694.jpeg"},{"id":92929618,"identity":"9c368e0b-a031-4bbe-97b9-819e9c03f808","added_by":"auto","created_at":"2025-10-07 08:50:28","extension":"jpeg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":652117,"visible":true,"origin":"","legend":"\u003cp\u003eCCN5 Inhibits Senescence in an in vivo Mouse Heart Model. (A) An experimental scheme is shown (created using Biorender). (B) Heart extract was immunoblotted for senescence marker proteins p53 and p21. Protein levels were quantified and normalized to GAPDH (n=7). Panel B is a composite from separate blots for clarity. The uncropped blots are presented in Supplementary information. (C) Heart sections were stained for SA-β-gal activity. Positive cells were counted in random fields and plotted as a percentages of total cell number (n=5) (D) Heart sections were immunostained with antibodies against γH2AX (purple) and counter-stained with Hoechst (blue). γH2AX foci were counted in random fields and plotted as a percentage of total nuclei (n=4). Scale bar: 50 μm (500μm for 2x images). Data are shown as the mean ± SD. (one-way ANOVA; *p \u0026lt; 0.05, **p \u0026lt; 0.01).\u003c/p\u003e","description":"","filename":"floatimage6.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/6c0d59a5f4e40f8059dda79f.jpeg"},{"id":103251154,"identity":"399ab122-428a-4156-83b9-d4d1bffa99f5","added_by":"auto","created_at":"2026-02-23 16:05:21","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2788527,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/c9e683d9-e2cb-44a2-bc76-7106b453545b.pdf"},{"id":92929402,"identity":"523b4d92-2926-46fc-aa08-779191ad1597","added_by":"auto","created_at":"2025-10-07 08:42:28","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":1095397,"visible":true,"origin":"","legend":"","description":"","filename":"JoetalScireportsupplementarydataRev.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7635827/v1/3cdb92e5c9cb0677409c62b1.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"The Matricellular Protein CCN5 (WISP2) inhibits Cellular Senescence in Cardiac Myocytes and Fibroblasts","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCardiovascular diseases, including cardiomyopathy, arrhythmia, and heart failure, remain a leading cause of global mortality, with their prevalence increasing alongside an aging population\u003csup\u003e\u003cspan additionalcitationids=\"CR2\" citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Recent studies have shown that cellular senescence is closely linked to the pathogenesis and progression of diverse cardiovascular diseases by driving structural and functional alterations in the myocardium\u003csup\u003e\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eStress-induced cellular senescence is a fundamental response to diverse insults such as DNA damage, mitochondrial dysfunction, and oncogenic activation. While it initially serves as a rapid protective mechanism, persistent senescence leads to detrimental consequences. Senescent cells are characterized by growth arrest, morphological changes, increased mitochondrial activity, and resistance to apoptotic stimuli. They also display a distinct phenotype known as the senescence-associated secretory phenotype (SASP), defined by the secretion of various cytokines, growth factors, and matrix metalloproteinases\u003csup\u003e\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eIn the heart, senescent cells contribute to interstitial fibrosis, chronic inflammation, and extracellular matrix remodeling, thereby driving both diastolic and systolic dysfunction\u003csup\u003e\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. The limited regenerative capacity of the myocardium further exacerbates these age-related changes, increasing vulnerability to stressors such as metabolic overload, hypertension, and ischemic injury. More specifically, senescent cardiac myocytes develop hypertrophy, mitochondrial dysfunction, impaired contractility, and abnormal conduction, ultimately leading to progressive myocardial dysfunction. Senescent cardiac fibroblasts undergo proliferative arrest yet remain metabolically active, characterized by enhanced secretion of SASP-associated factors\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eTwo primary strategies have been proposed for targeting senescent cardiac cells. The first employs senolytic drugs to selectively eliminate senescent cells, while the second utilizes senomorphic drugs to suppress deleterious features such as SASP\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Although various nutritional and pharmacological interventions have been investigated\u003csup\u003e\u003cspan additionalcitationids=\"CR15 CR16\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e, their effectiveness in preventing or reversing senescence-associated pathologies remains limited, underscoring the urgent need for novel therapeutic strategies.\u003c/p\u003e\u003cp\u003eCell communication network (CCN) proteins (CCN1-6) are matricellular proteins that regulate diverse cellular processes, including fibrosis, angiogenesis, and wound healing. While most CCN proteins contain four distinct domains, IGFBP, vWC, TSP-1, and CT, CCN5 uniquely lacks the CT domain\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. This structural distinction has led to the hypothesis that CCN5 may function as an endogenous inhibitor of other CCN members. Supporting this idea, our group has shown that CCN5 inhibits cardiac hypertrophy and fibrosis, at least in part, by counteracting CCN2 activity\u003csup\u003e\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. Previous studies further demonstrated that CCN1 and CCN2 promote fibroblast senescence\u003csup\u003e\u003cspan additionalcitationids=\"CR24 CR25\" citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. Therefore, we hypothesized that CCN5 may regulate cellular senescence by antagonizing CCN1 or CCN2.\u003c/p\u003e\u003cp\u003eIn the present study, we investigated the role of CCN5 in cellular senescence using cultured rat cardiac myocytes and fibroblasts. Our results demonstrated that CCN5 suppressed cellular senescence induced by doxorubicin and by SASP factors in these cells. Moreover, CCN5 attenuated myocardial infarction (MI)-induced cellular senescence in the mouse heart. These findings suggest that CCN5 may serve as a potential therapeutic target for anti-senescence strategies in the heart.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003eDoxorubicin (Dox) Induces Cellular Senescence in Cardiac Myocytes and Fibroblasts\u003c/h2\u003e\u003cp\u003eDoxorubicin (Dox) is known to induce cellular senescence in diverse cell types primarily by eliciting genotoxic stress\u003csup\u003e\u003cspan additionalcitationids=\"CR28\" citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. To establish cellular senescence in cultured rat cardiac myocytes (H9c2) and cardiac fibroblasts, cells were treated with 100 nM Dox for 24 hours. Senescence was then assessed using three readouts. First, the expression of cell cycle regulators p53 and p21 was evaluated by western blotting. Second, senescent cells were quantified by microscopic detection of senescence-associated (SA) β-galactosidase activity. Third, accumulation of the DNA damage marker γH2AX was examined by immunostaining. All three assays consistently demonstrated that Dox effectively induced cellular senescence in both cardiac myocytes and fibroblasts (Supplementary Fig.\u0026nbsp;1). Accordingly, this protocol was employed in subsequent experiments to induce cellular senescence \u003cem\u003ein vitro\u003c/em\u003e.\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eCCN5 inhibits Dox-induced Cellular Senescence in Cardiac Myocytes and Fibroblasts\u003c/h3\u003e\n\u003cp\u003eWe next examined whether CCN5 modulates Dox-induced cellular senescence in cardiac myocytes. After 24 hours of Dox treatment, the culture medium was replaced with fresh medium, and purified CCN5 protein (500 ng/mL) was added for an additional 24 hours (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). CCN5 treatment reduced the expression levels of p53 and p21 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e1\u003c/span\u003eB), decreased the number of SA-β-galactosidase-positive cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e1\u003c/span\u003eC), and lowered the number of γH2AX foci compared with untreated cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e1\u003c/span\u003eD). These results indicate that CCN5 suppresses cellular senescence in cardiac myocytes.\u003c/p\u003e\u003cp\u003eWe then performed similar experiments in cardiac fibroblasts (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). As in cardiac myocytes, CCN5 treatment reduced the levels of senescent marker proteins (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e2\u003c/span\u003eB), decreased the number of SA-β-galactosidase-positive cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e2\u003c/span\u003eC), and diminished γH2AX foci (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e2\u003c/span\u003eD). Together, these findings demonstrated that CCN5 inhibits Dox-induced cellular senescence in both cardiac myocytes and fibroblasts.\u003c/p\u003e\n\u003ch3\u003eCCN5 Inhibits SASP-induced Cellular Senescence in Cardiac Myocytes and Cardiac Fibroblasts\u003c/h3\u003e\n\u003cp\u003eSenescent cells secret diverse factors, including cytokines, growth factors, and matrix metalloproteinases, collectively termed SASP factors. These factors exert paracrine effects that drive neighboring healthy cells into cellular senescence. Previous studies have shown that SASP secreted from cardiac myocyte can induce cellular senescence in adjacent fibroblasts\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e, and vice versa, thereby synergistically accelerating cellular senescence in the heart.\u003c/p\u003e\u003cp\u003eWe first tested whether CCN5 prevents cellular senescence in cardiac myocytes upon the treatment with SASP secreted from cardiac fibroblasts (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). Cardiac fibroblasts were treated with Dox for 24 hours, followed by culture in fresh medium lacking Dox for an additional 24 hours. The resulting conditioned medium, enriched with SASP, was applied to cardiac myocytes in the presence or absence of purified CCN5 protein (500 ng/mL). Conditioned medium containing SASP induced cellular senescence in cardiac myocytes, as evidenced by elevated senescent markers (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e3\u003c/span\u003eB), an increased number of SA-β-galactosidase-positive cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e3\u003c/span\u003eC), and reduced γH2AX foci (Fig.\u0026nbsp;\u003cspan refid=\"Fig9\" class=\"InternalRef\"\u003e3\u003c/span\u003eD). All these effects were significantly suppressed by CCN5 treatment.\u003c/p\u003e\u003cp\u003eWe next performed similar experiments to test whether CCN5 prevents cellular senescence in cardiac fibroblasts exposed to SASP secreted from cardiac myocytes (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e4\u003c/span\u003eA). In this setting, SASP secreted from cardiac myocytes induced cellular senescence in cardiac fibroblasts, as shown by all readouts, which was markedly attenuated by CCN5 (Fig.\u0026nbsp;\u003cspan refid=\"Fig10\" class=\"InternalRef\"\u003e4\u003c/span\u003eB\u0026thinsp;~\u0026thinsp;D).\u003c/p\u003e\u003cp\u003eCollectively, these findings demonstrated that CCN5 inhibits senescence not only induced by Dox but also triggered by SASP secreted from neighboring cardiac cell types.\u003c/p\u003e\n\u003ch3\u003eCCN5 Restores Apoptotic Responses in Senescent Cardiac Myocytes and Fibroblasts\u003c/h3\u003e\n\u003cp\u003eSenescent cells are resistant to apoptotic stimuli, and their persistence is particularly detrimental in chronic disease states. We therefore tested whether CCN5 could restore apoptotic responsiveness in cardiac myocytes and fibroblasts. Cells were treated with Dox for 24 hours, followed by purified CCN5 protein for an additional 24 hours, as described above. Apoptosis was then induced by treatment with staurosporine (STS, 100 nM) for 9 hours (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e5\u003c/span\u003eA, D)\u003csup\u003e32\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eWestern blotting revealed that cleaved PARP (c-PARP) and cleaved caspase 3 (c-Caspase 3) were significantly elevated in non-senescent cells (Cont), but not in Dox-treated senescent cells (Dox). This implies that the senescent cardiac myocytes and fibroblasts are indeed resistant to STS. CCN5 treatment restored sensitivity to STS in both cardiac myocytes and fibroblasts, as indicated by increased c-PARP and c-Caspase 3 levels (Dox\u0026thinsp;+\u0026thinsp;CCN5) (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e5\u003c/span\u003eB, E). Consistently, TUNEL assays showed a marked reduction in TUNEL-positive cells in senescent cells (Dox) compared with controls (Cont), which was significantly reversed by CCN5 treatment (Dox\u0026thinsp;+\u0026thinsp;CCN5) (Fig.\u0026nbsp;\u003cspan refid=\"Fig11\" class=\"InternalRef\"\u003e5\u003c/span\u003eC, F).\u003c/p\u003e\u003cp\u003eTogether, these findings indicate that CCN5 normalizes the apoptotic response in senescent cardiac myocytes and fibroblasts.\u003c/p\u003e\u003cp\u003e\u003cb\u003eCCN5 Inhibits Senescence in an\u003c/b\u003e \u003cb\u003ein vivo\u003c/b\u003e \u003cb\u003eMouse Heart Model\u003c/b\u003e\u003c/p\u003e\u003cp\u003eWe have previously shown that short-term expression of CCN5 via direct intramyocardial injection of modified mRNA encoding CCN5 (ModRNA-CCN5) significantly ameliorates structural and functional deterioration in mouse hearts subjected to myocardial infarction (MI)\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Using the same model, we investigated whether CCN5 also modulates cellular senescence in the infarcted heart. Coronary artery ligation to induce MI and intramyocardial injection of ModRNA-CCN5 were performed sequentially on the same day. Hearts were harvested on day 7 for molecular and histological analyses (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e6\u003c/span\u003eA).\u003c/p\u003e\u003cp\u003eModRNA-mediated expression of CCN5 was confirmed by western blotting (Supplementary Fig.\u0026nbsp;2). MI markedly increased of p53 and p21 expression (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e6\u003c/span\u003eB), the area and intensity of SA-β-galactosidase positive cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e6\u003c/span\u003eC), and the number of γH2AX-foci (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e6\u003c/span\u003eD) compared with sham-operated control hearts. CCN5 treatment significantly attenuated all of these cellular senescence-associated changes (Fig.\u0026nbsp;\u003cspan refid=\"Fig12\" class=\"InternalRef\"\u003e6\u003c/span\u003eB\u0026thinsp;~\u0026thinsp;D). These findings indicate that CCN5 effectively inhibits cellular senescence \u003cem\u003ein vivo\u003c/em\u003e in mouse heart following MI.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study demonstrates that CCN5 inhibits cellular senescence in cardiac myocytes and fibroblasts induced by Dox, a widely used reagent for senescence induction. We further showed that CCN5 prevents cellular senescence in these cells driven by SASP factors secreted from neighboring cells in a reciprocal manner. SASP-mediated secondary senescence drives a positive feedback loop that accelerates the expansion of senescent cells \u003cem\u003ein vivo\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. The anti-senescent effect of CCN5 was further validated in an \u003cem\u003ein vivo\u003c/em\u003e model of MI-induced cardiac senescence. Collectively, these findings suggest that CCN5 represent a promising therapeutic target for modulating cellular senescence in the heart.\u003c/p\u003e\u003cp\u003eOther CCN members have been reported to exert context-dependent roles in regulating cellular senescence. For example, CCN1 induces cellular senescence in multiple organs, including the skin, liver, and heart, and in diverse range of cell types, including fibroblasts, chondrocytes, and carcinoma cells\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e. CCN2 has been shown to promote cellular senescence in skin fibroblast, which helps to restrict fibrosis during tissue repair\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e. Furthermore, CCN1 and CCN3 have been directly implicated in the pathology of osteoarthritis by inducing chondrocyte senescence\u003csup\u003e\u003cspan additionalcitationids=\"CR36\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e–\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\u003cp\u003eThis study was motivated by our previous findings that CCN5 antagonizes CCN2 activity in both the heart\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e and eye\u003csup\u003e\u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e–\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. CCN2 expression is elevated in failing hearts under various pathological insults and is closely associated with cardiac fibrosis. We previously demonstrated that CCN5 inhibits cardiac fibrosis at least in part by downregulating CCN2. Similarly, CCN2 levels are elevated in the mouse retina under multiple pathogenic conditions and are linked to neovascularization and degeneration of retinal pigmented epithelium. In this contexts as well, CCN5 suppressed retinal pathologies while concomitantly reducing CCN2 expression. Based on these findings, we hypothesized that CCN5 may inhibit cellular senescence in the heart by antagonizing CCN2 and possibly other CCN family members.\u003c/p\u003e\u003cp\u003eAlthough our data clearly demonstrate that CCN5 inhibits cellular senescence in the heart, the underlying molecular mechanism remains unclear. For example, CCN2 expression levels were unaltered following treatment with Dox\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e or SASP (data not shown). suggesting that suppression of the CCN2 is unlikely to account for the anti-senescence activity of CCN5. We previously showed that CCN5 reverses pre-formed cardiac fibrosis by actively inducing the reverse trans-differentiation of myofibroblasts\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. By analogy, CCN5 may similarly trigger a reverse process of cellular senescence.\u003c/p\u003e\u003cp\u003eGiven that CCN5 modulates cellular senescence induced by Dox and SASP, it may serve as a senomorphic strategy by preventing the onset of senescence. Moreover, through its ability to restore apoptotic sensitivity in senescent cells, CCN5 may also function as a senolytic strategy, promoting the removal of existing senescent cells.\u003c/p\u003e\u003cp\u003eOverall, this study elucidates an anti-senescent function CCN5 in the heart. Together with its previously identified anti-fibrotic activity, these findings position CCN5 as a promising therapeutic modality for a broad spectrum of heart diseases.\u003c/p\u003e"},{"header":"Methods","content":"\u003ch2\u003eCells and cell culture\u003c/h2\u003e\u003cp\u003eRat ventricular cardiac fibroblasts (Cell Applications) were cultured in FGM medium (Cell Applications). H9c2 cells were cultured in High-Glucose DMEM (HyClone, Cytiva) at 37°C in a 5% CO\u003csub\u003e2\u003c/sub\u003e incubator. HEK 293-F cells (Gibco, #R79007) were suspension-cultured in Freestyle 293 medium (Gibco, #12338018) at 37°C in an 8% CO\u003csub\u003e2\u003c/sub\u003e incubator with continuous shaking.\u003c/p\u003e\u003ch3\u003ePurification of Recombinant Proteins\u003c/h3\u003e\u003cp\u003ecDNAs encoding the full-length human CCN5 protein were subcloned into a pcDNA3.1-myc-his plasmid and subsequently transfected into HEK 293-F cells. One day prior to transfection, 1 x 10\u003csup\u003e6\u003c/sup\u003ecells were seeded into Freestyle 293 medium. On the day of transfection, plasmid DNA was diluted in Opti-MEM medium (Gibco, #51985034). FectoPRO transfection reagent (Polyplus, #116–001) was then added to the diluted plasmid DNA at a 1:1 ratio, and the mixture was incubated for 10 minutes at room temperature. The mixture was added to the cultured HEK 293-F cells. Three days’ post-transfection, the culture medium was collected and centrifuged at 2,000 × g for 10minutes. Proteins from the culture medium were purified using Capturem His-Tagged Purification Maxiprep Columns (Takara, #635715). The purified proteins were stored in a buffer containing 20 mM NaHPO\u003csub\u003e4\u003c/sub\u003e, 150 mM NaCl, and 250 mM imidazole at -70°C\u003csup\u003e42\u003c/sup\u003e.\u003c/p\u003e\u003ch2\u003eInduction of Senescence, CCN5 Treatment, and SASP-Containing Media Preparation\u003c/h2\u003e\u003cp\u003eSenescence was induced by administering doxorubicin (100 nM) to cells in growth media for 24 hours. Purified CCN5 protein (500ng/ml) was added to cells for 24hours in media containing 0.1% FBS. Staurosporine (100nM) was applied to cells after CCN5 treatment for 9hours. To test SASP, following 24hours of doxorubicin treatment and a single wash with PBS, the medium was replaced with growth medium containing 0.1% FBS to remove doxorubicin. Cells were then incubated for 24 hours to generate SASP-containing conditioned media (CM). CM were treated with CCN5 protein for 24hour.\u003c/p\u003e\u003ch2\u003eWestern Blotting\u003c/h2\u003e\u003cp\u003eCell lysates were solubilized in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, pH 8.0) supplemented with Protease Inhibitor Cocktail Set III (Merck Millipore, #535140). Cell lysates were quantified using a Pierce BCA Protein Assay Kit (Thermo Scientific, #23227), separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to polyvinylidene difluoride (PVDF) membranes (Merck Millipore, #IPVH00010). Blots were blocked with a 3% BSA solution and incubated with primary antibodies against p53(Abcam), p21(Abcam), p16 (Abcam, #ab32072), GAPDH (CST), beta-actin (Santa Cruz), PARP(CST), caspase3(CST) and cleaved-caspase3(CST) for 12–16 hours at 4°C. After washing with Tris-buffered saline containing 0.1% Tween 20 (TBS-T), blots were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Thermo Scientific, #31460 for rabbit, #31430 for mouse), and washed again. Signals were developed using a EZ-Western Lumi Pico Kit (Dogenbio, Seoul, Korea) and Western Femto ECL Kit (FEMTO-100) and were detected by Amersham™ ImageQuant™ 800 (Cytiva).\u003c/p\u003e\u003ch2\u003eSenescence-associated βgalactosidase (SA-βgal) assay\u003c/h2\u003e\u003cp\u003eSA-βgal assay was assessed according to the manufacturer’s protocol (CST #9860). For \u003cem\u003ein vitro\u003c/em\u003e SA-βgal assay, fibroblasts and myocytes were seeded on 6-well plates. Fluorescence microscopy and DIC images were captured from random fields in each well using an EVOS M7000. SA-βgal positive cells are normalized against Hoechst-positive nucleus. For \u003cem\u003ein vivo\u003c/em\u003e SA-βgal assay, frozen heart tissues were outlined with ImmEdge® Hydrophobic Barrier PAP Pen (H-4000) and soaked in SA-βgal staining solution. Fluorescence microscopy and DIC images were captured using Olympus research slide scanner. All assays were performed in at least triplicate, with at least 300-500cells counted per sample from randomly selected fields. SA-βgal signals were analyzed using ImageJ software. The same settings (threshold, color threshold, brightness, analyze particles) were applied for each experimental set. Color Thresholding was applied to selectively retain the blue-colored SA-βgal stained regions. Thresholding process was employed to eliminate background noise, enabling the accurate determination and analysis of both nuclei and the SA-βgal stained areas.\u003c/p\u003e\u003ch2\u003eImmunocytochemistry\u003c/h2\u003e\u003cp\u003eCells were seeded onto 16 mm coverslips. After CCN5 treatment, cells were fixed with 4% PFA, permeabilized with 0.2% Triton X-100, and blocked with a 5% BSA solution. Subsequently, cells were incubated with a primary antibody against γH2AX (JBW301, Merck), followed by incubation with Alexa Fluor 488 (Invitrogen, A11008) conjugated secondary antibodies. Hoechst 33342 dye was used for nuclear staining. Fluorescence microscopy images were captured using an Olympus fluorescent microscope. All assays were performed in at least triplicate, with at least 100 cells counted per sample from randomly selected fields. Immunofluorescence signals were analyzed using ImageJ software, applying the same settings (threshold, Gaussian distribution, analyze particles) for each experiment set. A Gaussian distribution-based image subtraction was applied to remove noise and extract foci. A thresholding process was also employed to eliminate background noise, enabling the accurate quantification and analysis of both nuclei and the γH2AX foci.\u003c/p\u003e\u003ch2\u003eTUNEL Assay\u003c/h2\u003e\u003cp\u003eTUNEL assay was performed according to the manufacturer’s instructions (DeadEnd Fluorometric TUNEL System (Promega, San Luis Obispo, CA, USA). The slides with seeded cells were treated with a TUNEL reaction mixture containing terminal deoxynucleotidyl transferase (TdT) and fluorescein UTP. The reaction was carried out in a humidified chamber at 37 ◦C for 1 hour. After the reaction, the slides were stained with Hoechst 33342 and examined under a fluorescent microscope (Olympus). Apoptotic signals and nuclear signals were counted using ImageJ software with a fixed threshold for each experiment, and the percentage of TUNEL-positive cells was calculated.\u003c/p\u003e\u003ch2\u003eAnimal Experiments and Myocardial Infarction Model\u003c/h2\u003e\u003cp\u003e All animal experimental procedures were approved by the Institutional Animal Care and Use Committees of Gwangju Institute of Science and Technology (GIST). All procedures were conducted in accordance with relevant guidelines and regulations for laboratory animals. This study is reported in accordance with ARRIVE guidelines. C57BL/6 mice (10–12-week-old males, 25–28 g body weight) were obtained from DBL Inc. (Eumseong, Korea). All efforts were made to minimize animal suffering. All mice were housed in an equipped animal facility with temperature of 18–23°C and humidity at 40–60%, under 12hous light/dark cycle, and had free access to food and water. To induce myocardial infarction model, mice were anesthetized by a mixture of 95 mg/kg ketamine (Yuhan, Korea) and 5 mg/kg xylazine (Bayer, Germany). The left side of the chest was shaved, and an intubation tube was inserted into the trachea. An incision was made in the fourth intercostal space, and the muscles were separated with scissors. The pericardium was gently removed. Myocardial infarction (MI) was induced by ligation of the left anterior descending (LAD) artery using a 7 − 0 black silk suture. The chest was sutured with 4 − 0 black silk. The same surgical procedure, without LAD ligation, was performed for the sham operation. Seven days post-surgery, isoflurane was used for anesthetization via inhalation before euthanasia. Mice were euthanized by cervical dislocation humanely performed by trained researchers in accordance with approved protocols. Harvested hearts were used for western blotting, senescence-associated β-galactosidase (SA-β-gal) assay, and immunohistochemistry.\u003c/p\u003e\u003ch2\u003eProduction of Modified mRNA-CCN5 and Injection\u003c/h2\u003e\u003cp\u003ePolyadenylated and capped (CleanCap™ technology) modified RNAs (ModRNAs) were synthesized by TriLink Biotechnologies (San Diego, CA, USA) with full substitution of uridine with pseudo-uridine. The 5′ and 3′ untranslated regions (UTRs) were designed by the Zangi lab (New York, NY, USA). ModRNAs and Lipofectamine RNAiMAX transfection reagent (Invitrogen, Waltham, MA, USA, #13778150) were separately diluted in Opti-MEM, mixed, and incubated for 15 minutes at room temperature. A total of 50 µg of the ModRNA mixture was directly injected into the endocardium adjacent to the infarcted area.\u003c/p\u003e\u003ch2\u003eHistology and Immunohistochemistry\u003c/h2\u003e\u003cp\u003eHarvested tissue samples were fixed in 4% paraformaldehyde for 72 hours at 4°C and incubated in 30% sucrose for 72 hours at 4°C as a cryoprotectant. The tissues were embedded in OCT compound (3801480, Leica, Germany). Frozen tissue blocks were sectioned at 8 µm thickness using a cryostat microtome (HM525NX, Thermo Scientific, USA). Sections were mounted on adhesive slides (J1800AMNZ, Epredia). For γH2AX, immunohistochemistry was performed, which included antigen retrieval by boiling in a pH 6 citrate buffer. Primary antibodies (JBW301, Merck, 1:250) were diluted in a 3% bovine serum albumin blocking solution and applied for incubation. Secondary Alexa Fluor 594 (Invitrogen, A11032) conjugated antibodies were then applied and visualized. Images were acquired using Olympus confocal microscopy (Olympus, Japan). Immunofluorescence signals were analyzed using ImageJ software applying the same settings (threshold, Gaussian distribution, analyze particles) for each experiment set. A Gaussian distribution-based image subtraction was applied to remove noise and extract foci. A thresholding process was employed to eliminate background noise, enabling the accurate quantification and analysis of both nuclei and the γH2AX foci.\u003c/p\u003e\u003ch2\u003eStatistical Analysis\u003c/h2\u003e\u003cp\u003eN numbers represent independent biological observations. All experiments were repeated independently at least three times. One-Way Analysis of Variance (ANOVA) was employed for statistical analyses to determine the significance of the data using GraphPad Prism 7 software (GraphPad Software, San Diego, CA). An asterisk (*, p ≤ 0.05) or a double asterisk (**, p ≤ 0.01) indicates statistical significance. Data are presented as the mean ± standard deviation.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eCompeting interests\u003c/h2\u003e\u003cp\u003eNo potential conflicts of interest exist for other authors.\u003c/p\u003e\u003c/p\u003e\u003ch2\u003eFunding\u003c/h2\u003e\u003cp\u003eThis study was supported by funding from the Korea\u0026ndash;US Collaborative Research Fund (RS-2024-00466906) and the National Research Council of Science \u0026amp; Technology(NST) grant by the Korea government (MSIT) (No. GTL24021-000).\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eConceptualization, S.P.J. and W.J.P.; methodology, J.Y.J. and M.Y.L.; validation, S.B.K., J.Y.J. and M.Y.L.; formal analysis, J.Y.J.; investigation, J.Y.J.; data curation, S.B.K. and S.P.J.; writing\u0026mdash;original draft preparation, J.Y.J.; writing\u0026mdash;review and editing, J.Y.J., S.P.J. and W.J.P.; supervision, S.P.J. and W.J.P.; Resources, T.H.K. and D.T.J.; project administration, W.J.P.; funding acquisition, W.J.P.\u003c/p\u003e\u003ch2\u003eAcknowledgement\u003c/h2\u003e\u003cp\u003eWe thank Dr. YS. Oh (Central Research Facility of Gwangju Institute of Science and Technology) for technical assistance of the confocal microscopy. Figures 1 A, 2 A, 3 A, 4 A, 5A and 5D were created with BioRender.com. (https://www.biorender.com, https://BioRender.com/w1x0kdx). During the preparation of this manuscript, the authors used ChatGPT (version 5.0) to assist with proofreading and improving the readability of the manuscript. All content was reviewed and edited by the authors, who take full responsibility for the final version of the publication.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eAll relevant data are within this paper and its Supporting Information files. The datasets used or analyzed during this study are available from the corresponding authors upon reasonable request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eMartin, S. S. \u003cem\u003eet al.\u003c/em\u003e 2025 Heart Disease and Stroke Statistics: A report of US and global data from the American Heart Association. \u003cem\u003eCirculation\u003c/em\u003e (2025) doi:10.1161/ cir.0000000000001303.\u003c/li\u003e\n\u003cli\u003eBeghini, A. \u003cem\u003eet al.\u003c/em\u003e 2024 update in heart failure. \u003cem\u003eESC Heart Failure\u003c/em\u003e (2024) doi:10.1002/ ehf2.14857.\u003c/li\u003e\n\u003cli\u003eWorld Health Organization: WHO Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2025).\u003c/li\u003e\n\u003cli\u003eLuan, Y. \u003cem\u003eet al.\u003c/em\u003e Cardiac cell senescence: molecular mechanisms, key proteins and therapeutic targets. \u003cem\u003eCell Death Discovery\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, (2024).\u003c/li\u003e\n\u003cli\u003eGrootaert, M. O. J. Cell senescence in cardiometabolic diseases. \u003cem\u003eNpj Aging\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, (2024).\u003c/li\u003e\n\u003cli\u003eEvangelou, K. \u003cem\u003eet al.\u003c/em\u003e Cellular senescence and cardiovascular diseases: moving to the \u0026ldquo;heart\u0026rdquo; of the problem. \u003cem\u003ePhysiological Reviews\u003c/em\u003e \u003cstrong\u003e103\u003c/strong\u003e, 609\u0026ndash;647 (2022).\u003c/li\u003e\n\u003cli\u003eGonz\u0026aacute;lez‐Gualda, E., Baker, A. G., Fruk, L. \u0026amp; Mu\u0026ntilde;oz‐Esp\u0026iacute;n, D. A guide to assessing cellular senescencein vitroandin vivo. \u003cem\u003eFEBS Journal\u003c/em\u003e \u003cstrong\u003e288\u003c/strong\u003e, 56\u0026ndash;80 (2020).\u003c/li\u003e\n\u003cli\u003eGorgoulis, V. \u003cem\u003eet al.\u003c/em\u003e Cellular senescence: defining a path forward. \u003cem\u003eCell\u003c/em\u003e \u003cstrong\u003e179\u003c/strong\u003e, 813\u0026ndash;827 (2019).\u003c/li\u003e\n\u003cli\u003eKumari, R. \u0026amp; Jat, P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. \u003cem\u003eFrontiers in Cell and Developmental Biology\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, (2021).\u003c/li\u003e\n\u003cli\u003eShimizu, I. \u0026amp; Minamino, T. Cellular senescence in cardiac diseases. \u003cem\u003eJournal of Cardiology\u003c/em\u003e \u003cstrong\u003e74\u003c/strong\u003e, 313\u0026ndash;319 (2019).\u003c/li\u003e\n\u003cli\u003eZhao, S., Zhang, Y., Zhao, Y. \u0026amp; Lu, X. Cellular senescence as a key player in Chronic heart failure pathogenesis: unraveling mechanisms and therapeutic opportunities. \u003cem\u003eProgress in Biophysics and Molecular Biology\u003c/em\u003e (2025) doi:10.1016/j.pbiomolbio.2025.02.002.\u003c/li\u003e\n\u003cli\u003eStojanović, S. D., Thum, T. \u0026amp; Bauersachs, J. Anti-senescence therapies: a new concept to address cardiovascular disease. \u003cem\u003eCardiovascular Research\u003c/em\u003e (2025) doi:10.1093/cvr/cvaf030.\u003c/li\u003e\n\u003cli\u003eSuda, M., Katsuumi, G., Tchkonia, T., Kirkland, J. L. \u0026amp; Minamino, T. Potential clinical implications of senotherapies for cardiovascular disease. \u003cem\u003eCirculation Journal\u003c/em\u003e \u003cstrong\u003e88\u003c/strong\u003e, 277\u0026ndash;284 (2023).\u003c/li\u003e\n\u003cli\u003eXia, W. \u003cem\u003eet al.\u003c/em\u003e Depletion of SASP senescent cardiomyocytes with senolytic drugs confers therapeutic effects in doxorubicin‐related cardiotoxicity. \u003cem\u003eFEBS Journal\u003c/em\u003e (2024) doi:10.1111/febs.17164.\u003c/li\u003e\n\u003cli\u003eScalise, M. \u003cem\u003eet al.\u003c/em\u003e Senolytics rejuvenate aging cardiomyopathy in human cardiac organoids. \u003cem\u003eMechanisms of Ageing and Development\u003c/em\u003e 112007 (2024) doi:10.1016/j.mad.2024.112007.\u003c/li\u003e\n\u003cli\u003eSalerno, N. \u003cem\u003eet al.\u003c/em\u003e Pharmacological clearance of senescent cells improves cardiac remodeling and function after myocardial infarction in female aged mice. \u003cem\u003eMechanisms of Ageing and Development\u003c/em\u003e \u003cstrong\u003e208\u003c/strong\u003e, 111740 (2022). \u003c/li\u003e\n\u003cli\u003eYang, B. et al. Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway. International Journal of Biological Sciences 20, 4314\u0026ndash;4340 (2024).\u003c/li\u003e\n\u003cli\u003eMonsen, V. T. \u0026amp; Attramadal, H. Structural insights into regulation of CCN protein activities and functions. \u003cem\u003eJournal of Cell Communication and Signaling\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 371\u0026ndash;390 (2023).\u003c/li\u003e\n\u003cli\u003eChen, C.-C. \u0026amp; Lau, L. F. Functions and mechanisms of action of CCN matricellular proteins. \u003cem\u003eThe International Journal of Biochemistry \u0026amp; Cell Biology\u003c/em\u003e \u003cstrong\u003e41\u003c/strong\u003e, 771\u0026ndash;783 (2008).\u003c/li\u003e\n\u003cli\u003eJeong, D. \u003cem\u003eet al.\u003c/em\u003e Matricellular protein CCN5 reverses established cardiac fibrosis. \u003cem\u003eJournal of the American College of Cardiology\u003c/em\u003e \u003cstrong\u003e67\u003c/strong\u003e, 1556\u0026ndash;1568 (2016).\u003c/li\u003e\n\u003cli\u003eYoon, P. O. \u003cem\u003eet al.\u003c/em\u003e The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. \u003cem\u003eJournal of Molecular and Cellular Cardiology\u003c/em\u003e \u003cstrong\u003e49\u003c/strong\u003e, 294\u0026ndash;303 (2010).\u003c/li\u003e\n\u003cli\u003eZhang, L., Li, Y., Liang, C. \u0026amp; Yang, W. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. \u003cem\u003eInternational Journal of Molecular Medicine\u003c/em\u003e \u003cstrong\u003e33\u003c/strong\u003e, 478\u0026ndash;486 (2013).\u003c/li\u003e\n\u003cli\u003eFeng, T. \u003cem\u003eet al.\u003c/em\u003e CCN1-Induced cellular senescence promotes heart regeneration. \u003cem\u003eCirculation\u003c/em\u003e \u003cstrong\u003e139\u003c/strong\u003e, 2495\u0026ndash;2498 (2019).\u003c/li\u003e\n\u003cli\u003eJun, J.-I. \u0026amp; Lau, L. F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. \u003cem\u003eNature Cell Biology\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 676\u0026ndash;685 (2010).\u003c/li\u003e\n\u003cli\u003eJun, J.-I. \u0026amp; Lau, L. F. CCN2 induces cellular senescence in fibroblasts. \u003cem\u003eJournal of Cell Communication and Signaling\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, 15\u0026ndash;23 (2016).\u003c/li\u003e\n\u003cli\u003eTejedor-Santamaria, L. \u003cem\u003eet al.\u003c/em\u003e CCN2 activates cellular senescence leading to kidney fibrosis in folic Acid-Induced experimental nephropathy. \u003cem\u003eInternational Journal of Molecular Sciences\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 4401 (2025).\u003c/li\u003e\n\u003cli\u003eVon Hoff, D. D. Risk factors for doxorubicin-lnduced congestive heart failure. \u003cem\u003eAnnals of Internal Medicine\u003c/em\u003e \u003cstrong\u003e91\u003c/strong\u003e, 710 (1979).\u003c/li\u003e\n\u003cli\u003eMaejima, Y., Adachi, S., Ito, H., Hirao, K. \u0026amp; Isobe, M. Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage. \u003cem\u003eAging Cell\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, 125\u0026ndash;136 (2007).\u003c/li\u003e\n\u003cli\u003eSpallarossa, P. \u003cem\u003eet al.\u003c/em\u003e Doxorubicin induces senescence or apoptosis in rat neonatal cardiomyocytes by regulating the expression levels of the telomere binding factors 1 and 2. \u003cem\u003eAJP Heart and Circulatory Physiology\u003c/em\u003e \u003cstrong\u003e297\u003c/strong\u003e, H2169\u0026ndash;H2181 (2009).\u003c/li\u003e\n\u003cli\u003eTang, X., Li, P.-H. \u0026amp; Chen, H.-Z. Cardiomyocyte senescence and cellular communications within myocardial microenvironments. \u003cem\u003eFrontiers in Endocrinology\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, (2020).\u003c/li\u003e\n\u003cli\u003eLewis‐McDougall, F. C. \u003cem\u003eet al.\u003c/em\u003e Aged‐senescent cells contribute to impaired heart regeneration. \u003cem\u003eAging Cell\u003c/em\u003e \u003cstrong\u003e18\u003c/strong\u003e, (2019).\u003c/li\u003e\n\u003cli\u003eKato, K. \u003cem\u003eet al.\u003c/em\u003e Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging. \u003cem\u003eAmerican Journal of Respiratory Cell and Molecular Biology\u003c/em\u003e \u003cstrong\u003e62\u003c/strong\u003e, 633\u0026ndash;644 (2020).\u003c/li\u003e\n\u003cli\u003eMagadum, A. \u003cem\u003eet al.\u003c/em\u003e Specific Modified mRNA translation System. \u003cem\u003eCirculation\u003c/em\u003e \u003cstrong\u003e142\u003c/strong\u003e, 2485\u0026ndash;2488 (2020).\u003c/li\u003e\n\u003cli\u003eSong, M. H. \u003cem\u003eet al.\u003c/em\u003e Modified mRNA-Mediated CCN5 Gene Transfer Ameliorates Cardiac Dysfunction and Fibrosis without Adverse Structural Remodeling. \u003cem\u003eInternational Journal of Molecular Sciences\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 6262 (2024).\u003c/li\u003e\n\u003cli\u003eFeng, M. \u003cem\u003eet al.\u003c/em\u003e Inhibition of cellular communication network factor 1 (CCN1)-driven senescence slows down cartilage inflammaging and osteoarthritis. \u003cem\u003eBone\u003c/em\u003e \u003cstrong\u003e139\u003c/strong\u003e, 115522 (2020).\u003c/li\u003e\n\u003cli\u003eKuwahara, M. \u003cem\u003eet al.\u003c/em\u003e CCN3 (NOV) drives degradative changes in aging articular cartilage. \u003cem\u003eInternational Journal of Molecular Sciences\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 7556 (2020).\u003c/li\u003e\n\u003cli\u003eFujita, M., Sasada, M., Iyoda, T. \u0026amp; Fukai, F. Involvement of matricellular proteins in cellular senescence: Potential therapeutic targets for Age-Related Diseases. \u003cem\u003eInternational Journal of Molecular Sciences\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 6591 (2024).\u003c/li\u003e\n\u003cli\u003eIm, S., Song, M. H., Elangovan, M., Woo, K. M. \u0026amp; Park, W. J. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium. \u003cem\u003eScientific Reports\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, (2024).\u003c/li\u003e\n\u003cli\u003eYoon, A.\u003cem\u003e et al.\u003c/em\u003e The matricellular protein CCN5 inhibits fibrotic deformation of retinal pigment epithelium. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, e0208897, doi:10.1371/journal.pone.0208897 (2018).\u003c/li\u003e\n\u003cli\u003eIm, S.\u003cem\u003e et al.\u003c/em\u003e Suppression of choroidal neovascularization and epithelial-mesenchymal transition in retinal pigmented epithelium by adeno-associated virus-mediated overexpression of CCN5 in mice. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, e0269937, doi:10.1371/journal.pone.0269937 (2022).\u003c/li\u003e\n\u003cli\u003ePatricelli, C., Lehmann, P., Oxford, J. T. \u0026amp; Pu, X. Doxorubicin-induced modulation of TGF-\u0026beta; signaling cascade in mouse fibroblasts: insights into cardiotoxicity mechanisms. \u003cem\u003eScientific Reports\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, (2023).\u003c/li\u003e\n\u003cli\u003eSong, M. H. \u003cem\u003eet al.\u003c/em\u003e The TSP-1 domain of the matricellular protein CCN5 is essential for its nuclear localization and anti-fibrotic function. \u003cem\u003ePLoS ONE\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, e0267629 (2022).\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"CCN5, WISP2, Cellular senescence, Cardiac myocytes, Cardiac fibroblasts","lastPublishedDoi":"10.21203/rs.3.rs-7635827/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7635827/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eCardiovascular diseases remain the leading cause of global mortality. Cellular senescence has recently been implicated in the pathogenesis of various cardiovascular diseases. Our group has previously shown that the matricellular protein CCN5 is a potent anti-fibrotic molecule capable of inhibiting and reversing cardiac fibrosis. In this study, we investigated whether CCN5 can modulate cellular senescence in the heart utilizing three readouts: western blotting for p53 and p21, staining for senescence-associated β-galactosidase, and microscopic analysis of γH2AX-positive foci. CCN5 effectively inhibited doxorubicin-induced cellular senescence in both cardiac myocytes and fibroblasts. In addition, CCN5 suppressed cellular senescence in cardiac myocytes induced by the senescence-associated secretory phenotype factors secreted from cardiac fibroblast, and \u003cem\u003evice versa\u003c/em\u003e. CCN5 also restored the apoptotic response of senescent cells. Finally, CCN5 attenuated myocardial infarction-induced cellular senescence in mice. Collectively, our findings provide novel insights into the potential role of CCN5 in the development of anti-senescence therapies.\u003c/p\u003e","manuscriptTitle":"The Matricellular Protein CCN5 (WISP2) inhibits Cellular Senescence in Cardiac Myocytes and Fibroblasts","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-10-07 08:42:23","doi":"10.21203/rs.3.rs-7635827/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-10-13T09:19:37+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-10-12T19:45:04+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-09-30T16:06:26+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"147738789720065468285638199306310714526","date":"2025-09-29T17:46:05+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-09-26T12:34:11+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"99693867561826471968618026705416555067","date":"2025-09-26T08:23:54+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"146805372302850905052421556130343527877","date":"2025-09-24T20:34:55+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-09-24T14:02:01+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-09-24T13:55:05+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-09-24T07:17:17+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-09-22T10:29:38+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-09-22T09:21:44+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"ebf7767f-6116-4593-9384-553792bc3e86","owner":[],"postedDate":"October 7th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":55798055,"name":"Health sciences/Cardiology"},{"id":55798056,"name":"Biological sciences/Cell biology"},{"id":55798057,"name":"Health sciences/Diseases"}],"tags":[],"updatedAt":"2026-02-23T16:02:22+00:00","versionOfRecord":{"articleIdentity":"rs-7635827","link":"https://doi.org/10.1038/s41598-026-40206-1","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2026-02-20 15:58:41","publishedOnDateReadable":"February 20th, 2026"},"versionCreatedAt":"2025-10-07 08:42:23","video":"","vorDoi":"10.1038/s41598-026-40206-1","vorDoiUrl":"https://doi.org/10.1038/s41598-026-40206-1","workflowStages":[]},"version":"v1","identity":"rs-7635827","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7635827","identity":"rs-7635827","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}